TAKAYASU ARTERITIS (TAK)
Clinical trials for TAKAYASU ARTERITIS (TAK) explained in plain language.
Never miss a new study
Get alerted when new TAKAYASU ARTERITIS (TAK) trials appear
Sign up with your email to follow new studies for TAKAYASU ARTERITIS (TAK), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. R…
Matched conditions: TAKAYASU ARTERITIS (TAK)
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New ultrasound score may better monitor rare artery disease
Knowledge-focused Not yet recruitingThis study will test whether a special ultrasound score, called OTUS, can accurately track disease activity in people with Takayasu arteritis, a rare condition that causes inflammation of the large arteries. Researchers will follow 100 patients with active disease, performing ult…
Matched conditions: TAKAYASU ARTERITIS (TAK)
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC